Applied Therapeutics Reports Q2 Loss
Applied Therapeutics (NASDAQ:APLT), a biotechnology company focused on developing treatments for rare metabolic diseases, reported earnings results for Q2 2025 on August 13, 2025. The main news from the release was the absence of recurring revenue and the continuation of operating losses, even as reported GAAP headline earnings per share outperformed analyst expectations. The company reported an EPS (GAAP) of $(0.15), GAAP earnings per share of $0.15 was greater than the estimated loss of $(0.17), but recognized $21.33 million in GAAP revenue, exceeding the $0.42 million GAAP forecast. Cash and cash equivalents (GAAP) dropped from $79.4 million as of December 31, 2024, to $30.4 million as of June 30, 2025, intensifying concerns over the firm’s financial sustainability in coming quarters. Overall, the period underscored progress in clinical programs but reinforced the urgent need for new capital or partnerships as losses mount.
Source: Analyst estimates for the quarter provided by FactSet.
Applied Therapeutics is dedicated to developing therapies for rare metabolic diseases where few treatment options exist. Its most advanced candidates target inherited metabolic disorders including classic galactosemia, SORD deficiency (also known as CMT-SORD), and PMM2-CDG.
Source Fool.com
